Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Painkiller panel drops...

    Painkiller panel drops experts linked to pharma industry

    Written by savita thakur thakur Published On 2016-07-08T14:25:32+05:30  |  Updated On 8 July 2016 2:25 PM IST

    Washington : A group advising the Food and Drug Administration on medical issues abruptly dropped four experts from a panel on prescription painkillers after concerns emerged about apparent ties to the pharmaceutical industry.


    The panel gathered in Washington on Wednesday for its first meeting, tasked with developing recommendations for the FDA on combating the problem of painkiller abuse and misuse. But four doctors listed on the panel's initial roster were dropped before the meeting.


    "We are not moving forward" with their nominations, said a spokeswoman for the National Academies of Sciences, Engineering and Medicine, which organized the panel. The national academies advise the federal government on medical, scientific and related issues. The FDA requested a report on the use of opioid painkillers after coming under fire for not doing enough to reduce fatal overdoses tied to the drugs, which have risen for the last 15 years.


    Federal advisers are supposed to be vetted for financial ties that can influence their judgment. Senator Ron Wyden of Oregon sent a letter Friday to the academies' leadership noting that two of the panel nominees had also served in professional societies that receive funding from drugmakers. Wyden has protested industry influence on federal expert panels before.


    One of the experts, Dr. Gregory Terman, said he was dismissed Tuesday afternoon by phone. He said he was told the decision was made because his nonprofit group, the American Pain Society, receives funding from drugmakers.


    "I responded that I'm very proud of my relationship with the American Pain Society, we're the only professional society in the world that thinks of pain science as priority No. 1," said Terman, in an interview with The Associated Press.


    Wyden's letter notes that the society has a "corporate council" of pharmaceutical manufacturers including Purdue Pharma, Pfizer Inc. and Teva Pharmaceuticals that contributed at least $132,500 to the group, according to online materials. Terman has served on the group's board of directors since 1998.


    A second panelist cited in Wyden's letter Mary Lynn McPherson received grants and residencies worth at least $300,000 that were sponsored or paid for by opioid drugmakers, according to a review of her work history cited by congressional staff. McPherson, who specializes in hospice and end-of-life care, is currently a professor at the University of Maryland School of Pharmacy.


    A university spokesman said in a statement that McPherson's funding was "not controlled or influenced in any way by the funding source."


    "Any implication that Dr. McPherson or her work has been compromised by association with pharmaceutical companies is deeply misguided."


    The national academies also dropped two other physicians specializing in pain care.


    Wyden notes in his letter: "My staff has been unable to thoroughly examine all of the members given the limited time available to review the provisional committee members."


    The highest-ranking Democrat on the Senate Finance Committee, Wyden has raised similar concerns about conflicts of interest on a pain panel organized by the National Institutes of Health. Last week he asked the director of NIH to turn over documents on how those experts are vetted.

    American Pain SocietyDrDr Gregory TermanNational Academies of SciencesNational Institutes of HealthNIHpainkillerPfizerPharma IndustryPurdue PharmaSenate Finance CommitteeSenator Ron WydenTeva PharmaceuticalsUS Food & Drug AdministrationUSFDA
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok